Clinical Trial: Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Comparative Treatment of Intravitreal Bevacizumab and Triamcinolone Acetonide on Diabetic Macular Edema
Brief Summary: One of the most frequent complications of diabetic retinopathy is diabetic macular edema. Recently, intravitreal bevacizumab and intravitreal triamcinolone were the most popular therapeutic modalities. However, as the long term effects of intravitreal bevacizumab and intravitreal triamcinolone on visual acuity and macular thickness have not been compared, it was the purpose of the present study to compare these treatment effects
Detailed Summary: Randomization of intravitreal bevacizumab, intravitreal triamcinolone, intravitreal bevacizumab with triamcinolone on eyes with diabetic macular edema
Sponsor: Hallym University Medical Center
Current Primary Outcome: Visual acuity [ Time Frame: baseline, 1 month, 3 months, 6month, 9 month, 12 month ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Central macular thickness [ Time Frame: baseline, 1 month, 3 months, 6 months, 12months ]
Original Secondary Outcome: Same as current
Information By: Hallym University Medical Center
Dates:
Date Received: April 25, 2011
Date Started: March 2009
Date Completion:
Last Updated: April 26, 2011
Last Verified: March 2009